Adjuvant Temodar dosing for glioblastoma – pro
Chemoradiation after resection is well established for glioblastoma. Three randomized studies, MR, EIRTC and RTOG have all showed a benefit for it. TEMODAR® (temozolomide) is indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment. NCCN also recommends combined chemoradiation.
The most popular way to dose Temodar is with the Stupp protocol, Temodar 75 mg/m2 for 42 days with radiation. In fact, this is the dose and schedule in the Prescribing Information.
Siew-Ju See, MRCP (UK), Mark R Gilbert Chemotherapy in Adults with Gliomas Ann Acad Med Singapore 2007;36:364-9
nccn, Centeral Nervous System, 2012
Mei-Yin C. Polley, Kathleen R. Lamborn, Susan M. Chang, Nicholas Butowski, Jennifer L. Clarke and Michael Prados
Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide Neuro Oncol (2010) 12 (3): 274-282.
Read the Layperson version here